Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

PRIVENAX 150 MG CAPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/PRIVENAX 150 MG CAPSULAS DURAS EFG

Approved

STANDARD

PRIVENAX 150 MG CAPSULAS DURAS EFG

Kern Pharma S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Dec 30, 2022
Approval ID: cd747bff9621cc7c
Company: Kern Pharma S.L.
Type: Standard

Approval Details

Approval Id: cd747bff9621cc7c
Drug Cima Aemps Name: PRIVENAX 150 MG CAPSULAS DURAS EFG
Register Number: 88471
Holder Company Name: Kern Pharma S.L.
Marketing Company Name: Kern Pharma S.L.
Holder Company Detail Path: /organization/kern-pharma-s-l
Marketing Company Detail Path: /organization/kern-pharma-s-l
Authorization Date: 2022-12-30
Dosage Form: CÁPSULA DURA
Dose: 150 MG
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Kern Pharma S.L.
Company Detail Path: /organization/kern-pharma-s-l

Company Information

Pharmaceutical Company Name: Kern Pharma S.L.
Country Name: Dominican Republic

Active Ingredients

DABIGATRAN ETEXILATO MESILATO

172,95 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Dec 30, 2022

Approval ID

cd747bff9621cc7c

Type

Standard

Back to CIMA-AEMPS Approvals